Decision to list Interventional Radiology products supplied by Culpan Distributors Ltd
We’re pleased to announce the approval of a listing agreement for Interventional Radiology products with Culpan Distributors Ltd (“Culpan”).
What we are doing
We’re pleased to announce the approval of a listing agreement for Interventional Radiology products with Culpan Distributors Ltd (“Culpan”).
In summary this will result in:
- 993 Interventional Radiology Products being listed in Part III of Section H of the Pharmaceutical Schedule from 1 May 2018
- National savings estimated at $49,000 per annum on the purchase of these products, assuming no change to current usage levels or product mix.
This Agreement would supersede any existing DHB contracts with this supplier for the devices listed in Schedule One of the Agreement.
The list of Culpan Interventional Radiology products will be available on PHARMAC's website from 1 May 2018, in both a PDF document and an Excel spreadsheet.
Any changes to the original proposal
This decision was subject to consultation letter dated 12 March 2018. No changes were made to the listing agreement as a result of consultation feedback.
Who we think will most be interested
- DHB staff
- Interventional radiology clinical staff
- Procurement officers
- Suppliers and wholesalers
Details about this decision
In September 2017 PHARMAC issued a request for proposals (“RFP”) for Interventional Radiology Products. The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After completing the RFP evaluation, and consulting on the provisional agreement reached with Culpan, PHARMAC has decided to list Culpan’s range of Interventional Radiology Products in Part III of Section H of the Pharmaceutical Schedule from 1 May 2018.
DHBs that purchase Culpan’s Interventional Radiology Products must do so under the terms and conditions, and at the prices, included in the Agreement, from 1 May 2018.
DHBs can continue to choose which Interventional Radiology Products they purchase.
Culpan’s products are the first Interventional Radiology products that PHARMAC has decided to list on the Pharmaceutical Schedule. Further consultations in this category are expected over the next few months.
Our response to what you told us
We’re really grateful for the time people took to respond to this consultation. A summary of the main themes raised in feedback, our responses to the feedback received are set out below:
|
Theme |
PHARMAC Staff Comment |
|---|---|
|
Request for clarification about one line-item that required a minimum volume commitment to access the list price |
Culpan confirmed that the minimum order will need to be met for DHBs to access the product. If unable to accept the minimum order, then the DHB will need to source the product elsewhere, e.g. a Logistics Provider or other supplier |
|
Clarification of scope of proposal |
Clarification provided |
|
Request for radiologist involvement with RFP; clarification regarding product list, selection and ability to add products to the Schedule. |
Clarification was provided regarding current national contract process and process to add products to Schedule. As DHBs ability to make products selection decisions is not altered by the proposed agreement, we do not expect any clinical impacts. |
If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.